Takeaki Uehara1, Mitsuhiro Takeno1, Maasa Hama1, Ryusuke Yoshimi1, Akiko Suda2, Atsushi Ihata3, Atsuhisa Ueda1, Ukihide Tateishi4, Yoshiaki Ishigatsubo1. 1. a Department of Internal Medicine and Clinical Immunology , Yokohama City University Graduate School of Medicine , Yokohama , Japan . 2. b Center for Rheumatic Diseases, Yokohama City University Medical Center , Yokohama , Japan . 3. c Department of Rheumatology and Infectious Disease , Yokohama Minami Kyosai Hospital , Yokohama , Japan , and. 4. d Department of Radiology , Graduate School of Medicine, Yokohama City University , Yokohama , Japan.
Abstract
OBJECTIVE: To examine clinical utility of (18)F-flurodeoxyglucose (FDG)-positron emission tomography (PET)/CT for assessment of interstitial lung disease (ILD) in patients with connective tissue diseases (CTDs). METHODS: A total of 69 (18)F-FDG PET/CT scans were conducted under deep inspiratory breath hold (DIBH) conditions in 45 CTD patients with ILD, including 16 dermatomyositis/polymyositis, nine systemic scleroderma and seven rheumatoid arthritis. Intensity and distribution of (18)F-FDG signals in PET/CT were determined by standardized uptake value (SUVmax) and visual score in 18 regions, respectively. ILD was defined as active when immunosuppressive therapy was initiated or intensified. RESULTS: Both SUVmax and visual score were higher in active phase (n = 32) than inactive phase (n = 37) (both p < 0.05), regardless of the underlying CTD and plain CT findings. The both parameters reduced after initiating or intensifying treatment in the follow-up study of 17 active patients except two died patients who showed increased visual score. Another two died patients showed high visual score (15 and 6/18, respectively). Changing ratio of visual score, but not SUVmax was correlated with KL-6 (r(2) = 0.38, p < 0.05) and CRP (r(2) = 0.52, p < 0.05). CONCLUSION: The DIBH (18)F-FDG PET/CT procedure sensitively illustrates active ILD lesions in CTD and the extended signal distribution is associated with unfavorable clinical outcome.
OBJECTIVE: To examine clinical utility of (18)F-flurodeoxyglucose (FDG)-positron emission tomography (PET)/CT for assessment of interstitial lung disease (ILD) in patients with connective tissue diseases (CTDs). METHODS: A total of 69 (18)F-FDG PET/CT scans were conducted under deep inspiratory breath hold (DIBH) conditions in 45 CTDpatients with ILD, including 16 dermatomyositis/polymyositis, nine systemic scleroderma and seven rheumatoid arthritis. Intensity and distribution of (18)F-FDG signals in PET/CT were determined by standardized uptake value (SUVmax) and visual score in 18 regions, respectively. ILD was defined as active when immunosuppressive therapy was initiated or intensified. RESULTS: Both SUVmax and visual score were higher in active phase (n = 32) than inactive phase (n = 37) (both p < 0.05), regardless of the underlying CTD and plain CT findings. The both parameters reduced after initiating or intensifying treatment in the follow-up study of 17 active patients except two died patients who showed increased visual score. Another two died patients showed high visual score (15 and 6/18, respectively). Changing ratio of visual score, but not SUVmax was correlated with KL-6 (r(2) = 0.38, p < 0.05) and CRP (r(2) = 0.52, p < 0.05). CONCLUSION: The DIBH (18)F-FDG PET/CT procedure sensitively illustrates active ILD lesions in CTD and the extended signal distribution is associated with unfavorable clinical outcome.
Authors: Sarah Geerts; Wim Wuyts; Ellen De Langhe; Jan Lenaerts; Jonas Yserbyt Journal: Sarcoidosis Vasc Diffuse Lung Dis Date: 2017-04-28 Impact factor: 0.670
Authors: Daphne M Peelen; Ben G J C Zwezerijnen; Esther J Nossent; Lilian J Meijboom; Otto S Hoekstra; Conny J Van der Laken; Alexandre E Voskuyl Journal: Rheumatology (Oxford) Date: 2020-06-01 Impact factor: 7.580
Authors: Nicholas D Weatherley; James A Eaden; Neil J Stewart; Brian J Bartholmai; Andrew J Swift; Stephen Mark Bianchi; Jim M Wild Journal: Thorax Date: 2019-03-18 Impact factor: 9.139
Authors: Bo Broens; Conny J van der Laken; Gerben J C Zwezerijnen; Esther J Nossent; Lilian J Meijboom; Julia Spierings; Jeska K de Vries-Bouwstra; Jacob M van Laar; Alexandre E Voskuyl Journal: Front Immunol Date: 2022-07-05 Impact factor: 8.786
Authors: M Grohs; F C Moazedi-Fuerst; H Flick; K Hackner; A Haidmayer; S Handzhiev; H Kiener; J Löffler-Ragg; G Mathis; G Mostbeck; O Schindler; G Widmann; H Prosch Journal: Z Rheumatol Date: 2022-05-05 Impact factor: 1.530